Every 424B that Altimmune, Inc. (ALT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALT filings page.
Altimmune, Inc. is conducting an underwritten offering of 64,250,000 shares of common stock together with accompanying common stock warrants and, in lieu of certain shares to some investors, pre-funded warrants to purchase up to 10,750,000 shares. The offering includes common stock warrants exercisable for up to 75,000,000 shares with a $3.00 exercise price.
Proceeds (net ~$211.2M) are intended to fund a planned global Phase 3 trial of pemvidutide in MASH and for working capital and general corporate purposes. The common stock warrants expire on the earlier of five years after issuance or 45 days after a public announcement of a successful Phase 3 pemvidutide readout. The pre-funded warrants have a $0.001 exercise price and do not expire.
Altimmune, Inc. filed a preliminary prospectus supplement to offer shares of common stock, pre-funded warrants and common stock warrants pursuant to its shelf registration statements. The company intends to use net proceeds to fund a planned global Phase 3 trial of pemvidutide in MASH and for working capital and general corporate purposes. The supplement notes pemvidutide Phase 2b topline efficacy (MASH resolution: 58.2% and 52.1% for two doses versus 19.9% for placebo) and that the FDA granted Breakthrough Therapy Designation in MASH. The filing discloses 110,882,735 shares outstanding as of December 31, 2025 and that the company filed to increase authorized common shares to 400,000,000 on April 16, 2026. The prospectus estimates available cash is expected to fund operations through a topline Phase 3 readout anticipated in the first half of 2029, subject to assumptions.
Altimmune, Inc. is conducting a registered direct offering of 12,397,920 shares of common stock and pre-funded warrants to purchase up to 4,647,534 additional shares, for a total offering price of $75,000,000. The company expects net proceeds of about $70.4 million after fees and expenses.
Altimmune plans to use the cash, together with existing resources, to advance clinical development and manufacturing for its lead drug pemvidutide, including preparation for a Phase 3 trial in MASH and potential commercial launch, and for general corporate purposes. Management currently expects available funds to support operations through the end of 2027, subject to development plans.
Altimmune, Inc. announced an at-the-market equity program to sell, from time to time, shares of its common stock for up to $200.0 million under a prospectus supplement, with Leerink Partners LLC acting as sales agent. Sales will be made as “at the market offerings” under Rule 415(a)(4) on Nasdaq (symbol ALT).
The sales agent will receive a commission of up to 3.0% of the aggregate gross sales price, and will be deemed an underwriter. Altimmune states it intends to use net proceeds for working capital and general corporate purposes, which may include R&D, clinical and regulatory activities, potential acquisitions or investments, and possible repayment or repurchase of securities.
Shares outstanding were 95,598,665 as of September 30, 2025. The company notes there is no escrow arrangement and no obligation for the sales agent to sell a specific amount; offerings may be suspended or terminated in accordance with the agreement.